Glaxo gift will reopen property debate

May 19, 1995

A new laboratory at Bradford University funded by pharmaceutical giant Glaxo has reopened the debate over ownership of intellectual property rights in joint ventures between academics and industry.

Glaxo has given Bradford Pounds 1.25 million over five years for research into a pioneering technique in supercritical fluids developed by PhD student Mazen Hanna.

Sir Mark Richmond, director of Wellcome Research and Development and former vice chancellor of Manchester University, said the joint venture could form a blueprint for similar collaborative programmes at other universities.

But he warned that despite enthusiasm from the pharmaceutical industry for working with universities in exploiting new technologies, their efforts were under threat because of misguided Government policy.

The Higher Education Funding Council for England's directive on generic research suggests that universities should own their own intellectual property rights. But Sir Mark stressed that patents were the lifeblood of the pharmaceutical industry.

It cost Pounds 150 million to bring a new drug to market, he said, and it was therefore crucial that property rights were retained by companies in the first instance. If this could not be secured then firms could be forced to seek overseas partners.

In the deal struck with Bradford, Glaxo has patented the technology and then reassigned the intellectual property back to the university to enable academics there to fully exploit its potential. This is because the technology is not part of Glaxo's core business. Glaxo will continue to make an intellectual input to the project but the university is free to approach other pharmaceutical companies to attract support. So far two firms have committed funding.

Mr Hanna, whose PhD thesis has just been submitted for examination, was originally funded by a Pounds 15,000 per year Glaxo studentship in 1992. His new technique, called Solution Enhanced Dispersion by Supercritical fluids, has important health and environmental implications since it allows drugs to be produced more precisely and with significantly fewer impurities. The technique could have applications for polymers and ceramics as well as pharmaceuticals.

* Glaxo has also given Pounds 1 million to Strathclyde University to fund research posts for young academics who will help advances in drug discovery.

The Glaxo-Jack research lecturerships honour Sir David Jack, former Glaxo Group research director and a Strathclyde graduate who was associated with Glaxo's work on new asthma treatments.

Already registered?

Sign in now if you are already registered or a current subscriber. Or subscribe for unrestricted access to our digital editions and iPad and iPhone app.

Have your say

Log in or register to post comments

Featured Jobs

Outreach & Partnerships Officer ZOOLOGICAL SOCIETY OF LONDON
Dean, Faculty of Arts and Social Sciences NATIONAL UNIVERSITY OF SINGAPORE
Academic Director (Primary) ST MARYS UNIVERSITY, TWICKENHAM
Vice-Chancellor MASSEY UNIVERSITY

Most Commented

Elderly woman looking up at sky

A recent paper claims that the quality of researchers declines with age. Five senior scientists consider the data and how they’ve contributed through the years

A keyboard with a 'donate' key

Richard Budd mulls the logic of giving money to your alma mater

Woman tearing up I can't sign

Schools and universities are increasingly looking at how improving personalities can boost social mobility. But in doing so, they may be forced to choose between teaching what is helpful, and what is true, says David Matthews

Eleanor Shakespeare illustration 19 May 2016

Tim Blackman’s vision of higher education for the 21st century is one in which students of varying abilities learn successfully together

Otto illustration (5 May 2016)

Craig Brandist on the proletarianisation of a profession and how it leads to behaviours that could hobble higher education